A systematic safety pipeline for selection of T-cell receptors to enter clinical use.


Journal

NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863

Informations de publication

Date de publication:
22 Aug 2023
Historique:
received: 19 10 2022
accepted: 31 07 2023
medline: 23 8 2023
pubmed: 23 8 2023
entrez: 22 8 2023
Statut: epublish

Résumé

Cancer immunotherapy using T cell receptor-engineered T cells (TCR-Ts) represents a promising treatment option. However, technologies for pre-clinical safety assessment are incomplete or inaccessible to most laboratories. Here, TCR-T off-target reactivity was assessed in five steps: (1) Mapping target amino acids necessary for TCR-T recognition, followed by (2) a computational search for, and (3) reactivity screening against, candidate cross-reactive peptides in the human proteome. Natural processing and presentation of recognized peptides was evaluated using (4) short mRNAs, and (5) full-length proteins. TCR-Ts were screened for recognition of unintended HLA alleles, and as proxy for off-target reactivity in vivo, a syngeneic, HLA-A*02:01-transgenic mouse model was used. Validation demonstrated importance of studying recognition of full-length candidate off-targets, and that the clinically applied 1G4 TCR has a hitherto unknown reactivity to unintended HLA alleles, relevant for patient selection. This widely applicable strategy should facilitate evaluation of candidate therapeutic TCRs and inform clinical decision-making.

Identifiants

pubmed: 37607971
doi: 10.1038/s41541-023-00713-y
pii: 10.1038/s41541-023-00713-y
pmc: PMC10444760
doi:

Types de publication

Journal Article

Langues

eng

Pagination

126

Subventions

Organisme : NCI NIH HHS
ID : R01 CA022677
Pays : United States

Informations de copyright

© 2023. Springer Nature Limited.

Références

Immunol Today. 1999 Apr;20(4):180-3
pubmed: 10203716
Immunooncol Technol. 2019 Sep;2:1-10
pubmed: 35036898
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17224-9
pubmed: 25413365
Curr Opin Immunol. 2022 Feb;74:190-198
pubmed: 34389174
J Biol Chem. 2003 Nov 21;278(47):46461-72
pubmed: 12963723
Oncoimmunology. 2018 Nov 20;8(2):e1532759
pubmed: 30713784
Blood. 2011 Jul 28;118(4):946-54
pubmed: 21613253
J Exp Med. 2005 Apr 18;201(8):1243-55
pubmed: 15837811
J Biol Chem. 2012 Jan 6;287(2):1168-77
pubmed: 22102287
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5387-92
pubmed: 10779548
Leukemia. 2010 Nov;24(11):1901-9
pubmed: 20844564
Front Immunol. 2019 Oct 22;10:2501
pubmed: 31695703
Sci Transl Med. 2013 Aug 7;5(197):197ra103
pubmed: 23926201
Blood Adv. 2019 Jul 9;3(13):2022-2034
pubmed: 31289029
Science. 2016 Jun 10;352(6291):1337-41
pubmed: 27198675
Clin Cancer Res. 2015 Mar 1;21(5):1019-27
pubmed: 25538264
Front Immunol. 2020 Apr 27;11:623
pubmed: 32425926
Sci Immunol. 2021 Dec 17;6(66):eabj4026
pubmed: 34919442
Nat Med. 2015 Aug;21(8):914-921
pubmed: 26193344
Scand J Immunol. 2009 Apr;69(4):319-28
pubmed: 19284496
Nucleic Acids Res. 2002 Jan 1;30(1):235-8
pubmed: 11752303
Nat Biotechnol. 2022 Apr;40(4):488-498
pubmed: 34873326
J Immunol. 2014 Jan 1;192(1):206-13
pubmed: 24293634
Clin Cancer Res. 2017 Oct 15;23(20):6012-6020
pubmed: 28645940
Nat Biotechnol. 2015 Mar;33(3):306-12
pubmed: 25485619
J Clin Invest. 2016 Mar 1;126(3):854-8
pubmed: 26808500
Front Immunol. 2022 Mar 03;13:835762
pubmed: 35309357
Semin Cell Dev Biol. 2018 Dec;84:30-41
pubmed: 30449534
J Clin Oncol. 2017 Oct 10;35(29):3322-3329
pubmed: 28809608
Nature. 2014 Nov 20;515(7527):355-64
pubmed: 25409824
Nat Med. 2010 Sep;16(9):1029-34
pubmed: 20693993
Gene Ther. 2000 Jun;7(12):1063-6
pubmed: 10871756
J Immunol. 2016 Apr 1;196(7):2915-22
pubmed: 26994303
Cell. 2014 May 22;157(5):1073-87
pubmed: 24855945
J Clin Oncol. 2019 Oct 20;37(30):2759-2768
pubmed: 31408414
Oncoimmunology. 2019 Nov 24;9(1):1682381
pubmed: 32002290
Cell. 2018 Jul 26;174(3):672-687.e27
pubmed: 30053426
Cancer Cell. 2013 Apr 15;23(4):516-26
pubmed: 23597565
J Exp Med. 1997 Jun 16;185(12):2043-51
pubmed: 9182675
Blood. 2009 Sep 3;114(10):2131-9
pubmed: 19587379
Oncoimmunology. 2016 Feb 18;5(5):e1138199
pubmed: 27467957
J Immunother. 2013 Feb;36(2):133-51
pubmed: 23377668
Cell. 2019 Aug 8;178(4):1016-1028.e13
pubmed: 31398327
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
Blood. 2013 Aug 8;122(6):863-71
pubmed: 23770775
BMC Immunol. 2008 Jan 22;9:1
pubmed: 18211710
J Immunol. 2008 May 1;180(9):6116-31
pubmed: 18424733
Annu Rev Immunol. 2006;24:419-66
pubmed: 16551255
Front Immunol. 2020 Apr 27;11:607
pubmed: 32395117
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W281-7
pubmed: 22638583

Auteurs

Zsofia Foldvari (Z)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Cathrine Knetter (C)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Weiwen Yang (W)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Thea Johanne Gjerdingen (TJ)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Ravi Chand Bollineni (RC)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Trung The Tran (TT)

Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.

Fridtjof Lund-Johansen (F)

Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.

Arne Kolstad (A)

Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.

Kimberley Drousch (K)

Institute of Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Robert Klopfleisch (R)

Institute of Veterinary Pathology, Freie Universität Berlin, Berlin, Germany.

Matthias Leisegang (M)

Institute of Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany. matthias.leisegang@charite.de.
David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL, USA. matthias.leisegang@charite.de.
German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany. matthias.leisegang@charite.de.

Johanna Olweus (J)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. johanna.olweus@medisin.uio.no.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. johanna.olweus@medisin.uio.no.

Classifications MeSH